PepGen Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Developments
BOSTON, March 23, 2023 (GLOBE NEWSWIRE) — PepGen Inc. (Nasdaq:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2022 and highlighted recent corporate developments.
Related news for (PEPG)
- PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update
- PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
- 24/7 Market News Snapshot 08 May, 2025 – PepGen Inc. Common Stock (NASDAQ:PEPG)
- Today’s Top Performers: MoBot’s Market Review 03/11/25 06:00 PM
- Don’t Miss Out: MoBot’s Latest Stock Updates 03/11/25 05:00 PM